Development, validity and responsiveness of the Clinical COPD Questionnaire

Thys van der Molen, Brigitte W M Willemse, Siebrig Schokker, Nick H T ten Hacken, Dirkje S Postma, Elizabeth F Juniper, Thys van der Molen, Brigitte W M Willemse, Siebrig Schokker, Nick H T ten Hacken, Dirkje S Postma, Elizabeth F Juniper

Abstract

Background: The new Global Obstructive Lung Disease (GOLD) guidelines advice to focus treatment in Chronic Obstructive Pulmonary Disease (COPD) on improvement of functional state, prevention of disease progression and minimization of symptoms. So far no validated questionnaires are available to measure symptom and functional state in daily clinical practice. The aim of this study was to develop and validate the Clinical COPD Questionnaire (CCQ).

Methods: Qualitative research with patients and clinicians was performed to generate possible items to evaluate clinical COPD control. Thereafter, an item reduction questionnaire was sent to 77 international experts. Sixty-seven experts responded and the 10 most important items, divided into 3 domains (symptoms, functional and mental state) were included in the CCQ (scale: 0 = best, 6 = worst).

Results: Cross-sectional data were collected from 119 subjects (57 COPD, GOLD stage I-III; 18 GOLD stage 0 and 44 (ex)smokers). Cronbach's alpha was high (0.91). The CCQ scores in patients (GOLD 0-III) were significantly higher than in healthy (ex)smokers. Furthermore, significant correlations were found between the CCQ total score and domains of the SF-36 (rho = 0.48 to rho = 0.69) and the SGRQ (rho = 0.67 to rho = 0.72). In patients with COPD, the correlation between the CCQ and FEV1%pred was rho =-0.49. Test-retest reliability was determined in 20 subjects in a 2-week interval (Intra Class Coefficient = 0.94). Thirty-six smokers with and without COPD showed significant improvement in the CCQ after 2 months smoking cessation, indicating the responsiveness of the CCQ.

Conclusion: The CCQ is a self-administered questionnaire specially developed to measure clinical control in patients with COPD. Data support the validity, reliability and responsiveness of this short and easy to administer questionnaire.

Figures

Figure 1
Figure 1
CCQ questionnaire Calculation of scores: CCQ total score = (item 1 + 2 + 3 + 4 + 5 + 6 + 7 + 8 + 9 + 10)/10; Symptom = (item 1 + 2 + 5 + 6)/4; Functional state = (item 7 + 8 + 9 + 10)/4; Mental state = (item 3 + 4)/2
Figure 2
Figure 2
Correlation between CCQ and FEV1 %predicted in patients with COPD (n = 58) CCQ = Clinical COPD Questionnaire

References

    1. Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P, Yernault JC, Decramer M, Higenbottam T, Postma DS, Rees J. Optimal assessment and management of chronic obstructive pulmonary disease (COPD): a consensus statement of the European Respiratory Society. Eur Respir J. 1995;8:1398–1420. doi: 10.1183/09031936.95.08081398.
    1. Murray CLJ, Lopez AD. Alternative projection of mortality and disability by cause 1990–2020: global burden of disease study. Lancet. 1997;394:1498–1504. doi: 10.1016/S0140-6736(96)07492-2.
    1. Feenstra TL, van Genugten ML, Hoogenveen RT, Wouters EF, Rutten-van Molken MP. The impact of aging and smoking on the future of chronic obstructive pulmonary disease: a model analysis in the Netherlands. Am J Respir Crit Care Med. 2001;164:590–596.
    1. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of chronic airflow limitation – the St George Respiratory Questionnaire. Am Rev Respir Dis. 1992;145:1321–1327.
    1. Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax. 1987;42:773–778.
    1. Maille AR, Koning CJ, Zwinderman AH, Willems LN, Dijkman JH, Kaptein AA. The development of the Quality of life for Respiratory Illness questionnaire (QOL-RIQ): a disease-specific quality of life questionnaire for patients with mild to moderate chronic non-specific lung disease. Respir Med. 1997;91:297–309.
    1. Donohue JF, van Noord JA, Bateman ED, Langley SJ, Lee A, Witek TJ, Kesten S, Towse L. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest. 2002;122:47–55. doi: 10.1378/chest.122.1.47.
    1. Wijkstra PJ, Van Altena R, Kraan J, Otten V, Postma DS, Koeter GH. Quality of life in patients with chronic obstructive pulmonary disease improves after rehabilitation at home. Eur Respir J. 1994;7:269–73.
    1. Spencer S, Calverly PM, Sherwood-Burge P, Jones PW. Health Status deteriration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163:122–8.
    1. Jones PW. Issues concerning health-related quality of life in COPD. Chest. 1995;107:187s–193s.
    1. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. the GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163:1256–1276.
    1. Juniper EF, Guyatt GH, Jaeschke R. How to develop and validate a new quality of life instrument. In: Spilker B, editor. Quality of Life and Pharmacoeconomics in Clinical Trials. Second. Raven Press Ltd, New York; 1995. pp. 49–56.
    1. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14:902–907. doi: 10.1034/j.1399-3003.1999.14d29.x.
    1. Ware JJ, Sherbourne CD. The MOS 36-item short form health survey (SF-36): I. Conceptual framework and item selection. Med Care. 1992;30:473–483.
    1. Jones PW. Quality of life measurement for patients with diseases of the airways. Thorax. 1991;46:676–682.
    1. Kanner RE, Anthonisen Nicholas R, Connett JE. Lower respiratory illnesses promote FEV1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med. 2001;164:358–364.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi